Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control

Area of Science:

• Cardiovascular Pharmacology
• Endocrinology
• Hematology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardiovascular protective effects beyond glucose lowering and weight reduction.
• The precise mechanisms underlying these cardioprotective benefits are not fully understood.
• Platelet function modulation is a potential contributing factor to the observed cardiovascular advantages of GLP-1 RAs.

Purpose of the Study:

• To review and synthesize existing preclinical and clinical evidence on the impact of GLP-1 RAs on platelet activation and function.
• To explore the potential antiplatelet mechanisms of GLP-1 RAs.
• To assess the clinical relevance of GLP-1 RA-mediated platelet modulation for cardiovascular risk reduction.

Main Methods:

• Literature review of preclinical studies investigating GLP-1 RA effects on platelet function.
• Analysis of clinical trial data examining platelet activation markers in patients treated with GLP-1 RAs.
• Synthesis of data focusing on receptor-dependent and -independent pathways, signaling molecules, and specific conditions like inflammation and shear stress.

Main Results:

• Preclinical data suggest GLP-1 RAs can decrease platelet activation through cyclic adenosine monophosphate signaling, increased nitric oxide bioavailability, and suppression of thromboxane pathways.
• Clinical studies, though limited and heterogeneous, indicate a reduction in platelet activation markers with GLP-1 RA use, independent of glycemic control or weight loss.
• Evidence points to potential antiplatelet effects of GLP-1 RAs, particularly under inflammatory or high shear stress conditions.

Conclusions:

• Existing evidence supports that GLP-1 RAs possess antiplatelet properties that may contribute to their cardioprotective profile.
• Platelet modulation by GLP-1 RAs warrants further investigation for its role in cardiovascular risk reduction.
• Larger, well-designed clinical studies are essential to elucidate the clinical significance of these antiplatelet effects.